Comparative Pharmacology
Head-to-head clinical analysis: ZANTAC 150 versus ZANTAC 75.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ZANTAC 150 versus ZANTAC 75.
ZANTAC 150 vs ZANTAC 75
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive histamine H2-receptor antagonist that inhibits basal and stimulated gastric acid secretion by blocking H2 receptors on parietal cells in the stomach.
Competitive inhibitor of histamine at H2 receptors on gastric parietal cells, reducing basal and stimulated gastric acid secretion.
150 mg orally twice daily or 300 mg orally once daily at bedtime.
75 mg orally once daily or 150 mg orally once daily for heartburn; up to 300 mg/day for duodenal ulcer or GERD.
None Documented
None Documented
2.5 hours (range 1.5-3.5 h); prolonged in renal impairment (creatinine clearance <50 mL/min: 4-8 h).
Terminal elimination half-life is 2.5-3 hours. In elderly patients or those with renal impairment (CrCl <50 mL/min), half-life may extend to 4-6 hours, requiring dose adjustment.
Renal (70% unchanged via tubular secretion), biliary (30% as metabolites and unchanged drug).
Renal (60-70% as unchanged drug), hepatic metabolism (30-40% as N-oxide, S-oxide, and desmethyl metabolites), with fecal excretion accounting for <10%.
Category C
Category C
H2 Antagonist
H2 Antagonist